Clinical Trial Update: A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva [Phase 2]

View source ↗

Summary

Phase 2 trial update for REGN2477 in fibrodysplasia ossificans progressiva (FOP) evaluating safety, tolerability, and effects on abnormal bone formation; study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrodysplasia Ossificans Progressiva

Drugs mentioned

• REGN2477

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Fibrodysplasia Ossificans Progressiva | Phase 2 | Status: COMPLETED | Results posted: 2022-12-02